Stockwatch: MonarchE And Tug-Of-War Drug Development
When One Drug Succeeds, Is It Curtains For The Competition?
Executive Summary
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?